The documented record for this applicant centers on one instrument platform and one open enforcement file. FDA's enforcement database lists BioMerieux SA, at Chemin De L'Orme, Marcy L'Etoile, France, as the recalling firm for the EMAG system, model 418591/418591U, described as an automated nucleic acid sample preparation instrument for IVD use. The recall is Class II, firm-initiated and voluntary, with a report date of November 4, 2026. FDA's establishment registration database separately lists BIOMERIEUX SA at the same Marcy L'Etoile address with an active registration status dated 2026. That address is a filing address, not a verified headquarters. [1][6]
The EMAG platform as documented
bioMérieux's corporate product page describes EMAG as a nucleic acid extraction system and a fully automated extraction platform for total nucleic acid purification, with product availability varying by country. The same page states CE marking according to IVD Regulation 2017/746 and links an EMAG brochure and a separate EMAG cybersecurity brochure. The U.S. product page frames the instrument around a standardized workflow for all samples, lab productivity, simplicity of use and confidence in extraction results. [3][4]
The EMAG brochure states 48 eluates in 98 minutes, five predefined workflows, 10 minutes hands-on time, two independent sections and one set of reagents for all samples. It also cites over 15 years of experience with more than 250 publications and more than five safety parts against contamination. These are the manufacturer's published figures, not independently verified results. [5]
Recall scope and reason
The enforcement record gives the reason for recall as delayed or no result when analyzing clinical samples with the EMAG system due to a randomly occurring software error, Error 10003 heater timeout, after updating to recent firmware SP4 Patch 2. The product quantity is listed as 33 units, identified by UDI-DI 357302BUDI000544TP and a set of serial numbers. The recall status is Ongoing, with a recall initiation date of September 11, 2026, initial firm notification by letter, and a center classification date of October 27, 2026. [1]
Distribution is described as worldwide to the United States, with nationwide distribution in California, Indiana, Kansas, Louisiana, Minnesota, Missouri, New York, Ohio and Texas, plus Canada, the United Kingdom, Sweden, France, Norway, the Netherlands, Belgium, Denmark, Germany and Austria. FDA's recall database entry for the same event carries the title Class 2 Device Recall EMAG. [1][2]
Adjacent product context
bioMérieux's ARGENE Solutions page places EMAG within a broader molecular testing range spanning extraction systems and real-time PCR assays, describing flexibility across viral infections and sample types. The page attributes same-day results and support for treatment decisions to that range. The public documents do not document specific assay performance, customer names or commercial availability beyond the stated country-variation disclaimers. [8][3]
Corporate and filing footprint
The 2025 Universal Registration Document is presented as including the annual financial report and states that consolidated financial statements are in millions of euros, with approval by the Annual General Meeting on May 28, 2026. FDA's establishment registration database lists BIOMERIEUX SA at Chemin De L'Orme, Marcy L'Etoile, Rhone 69280, France, registration number 8020790, FEI number 1000611339, status Active, date of registration status 2026. A second registration page for BIOMERIEUX SA appears in the sources but its full establishment details are not captured. [9][6][7]

